Nothing at all negative in what I am saying here, Just correcting sunstar's math. In the long run the total events will certainly be 1:1.
ex, you are not going to give no chance for complete responses ? More patients in the Bavi arm will certainly have better ECOG status and that factor.... just may be enough to allow for some complete responses.
Time will tell.
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!